FINHUB Insights

JNJ · Q3 FY25 · Jun 30 – Sep 28, 2025

Johnson & Johnson Q3 FY25: where the revenue came from and where it went

Johnson & Johnson Q3 FY25: revenue $24B (+7% year over year). Net profit $5.2B. Largest cohort Innovative Medicine $15.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jun 30 – Sep 28, 2025
Reported
Oct 22, 2025 10-Q
Sankey diagram of Johnson & Johnson's income statement for Q3 FY25: revenue of $24 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$24B +7% year over year
Gross profit$16.7B 70% margin
Operating profit$7.1B 30% margin
Net profit$5.2B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 28, 2025).
ItemValueShare of revenueYear over year
Revenue 24 100% +7%
Innovative Medicine 15.6 65% +7%
Med Tech 8.4 35% +7%
Cost of revenue−7.330%
Gross profit16.770% margin+1pp
SG&A−5.925%+0pp
Other−3.715%+0pp
Operating profit7.130% margin+0pp
Tax−2.3
Net profit5.221%+9pp
Filing on EDGAR More quarters of JNJ

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters